Fabry ERT Greenovation (Phase 1 klinische Studie)
Laufzeit: 01.01.2017 - 31.12.2017
imported
Kurzfassung
AN OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF MOSS-aGAL IN PATIENTS WITH FABRY DISEASE
